Sodium Selenate as a Disease-Modifying Treatment for Mild to Moderate Alzheimer’s Disease: An Open-Label Extension Study

    December 2021 in “ BMJ neurology open ”
    Lucy Vivash, Charles B Malpas, Christopher M. Hovens … Terence J. O’Brien
    Studysummary This study on Alzheimer's patients found that chronic sodium selenate treatment (up to 23 months) was safe and well-tolerated, with most adverse events being mild, and suggested potential slowing of cognitive decline, though confirmation requires further controlled studies.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on neurologyopen.bmj.com →
    Discuss this study in the Community →